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Abstract A full-length cDNA encoding the putative hepatic gly- 
cogen-binding (G,) subunit of protein phosphatase-1 (PPl) was 
isolated from a rat liver library. The deduced amino acid sequence 
(284 residues, 32.6 kDa) was 23% identical (39% similar) to the 
N-terminal region of the glycogen-binding (G,) subunit of PPl 
from striated muscle. The similarities between GM and G, were 
most striking between residues 63-f&& 16166 and 186-227 of 
human G, (-40% identity), nearly all the identities with the puta- 
tive yeast homologue GACl being located between 144-166 and 
186-227. The cDNA was expressed in E. coli, and the expressed 
protein transformed the properties of PPl to those characteristic 
of the hepatic glycogen-associated enzyme. These experiments 
establish that the cloned protein is G,. 
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1. Introduction 
Protein phosphatase-I (PPl) is one of the major protein 
serine/threonine phosphatase catalytic subunits found in eukar- 
yotic cells. In recent years, evidence has accumulated that this 
enzyme is regulated by ‘targetting’ subunits which tailor its 
properties to a particular cellular function. The interaction of 
PPI with a targetting subunit not only directs it to a specific 
location, but may enhance its activity towards some substrates, 
decrease its activity towards others and/or confer critical regu- 
latory properties upon it. Targetting subunits have been identi- 
fied which direct PPl to glycogen particles and membranes, the 
muscle contractile apparatus and nuclei, but many more are 
likely to be identified in the future (reviewed in [l]). 
A remarkable feature of this system is that the targetting 
subunits which direct PPl to the same location in different 
tissues are tissue specific, and alter the specificity and regula- 
tory properties of PPl in different ways. For example, the 
M,,,-subunit which targets PPl to the myofibrils of smooth 
muscle enhances the rate at which PPl dephosphorylates 
smooth muscle myosin, but not the rate at which it dephospho- 
rylates skeletal muscle myosin. In contrast, the structurally 
related M-subunit which targets PPl to the myofibrils of stri- 
ated muscles, enhances the rate at which PPI dephosphorylates 
skeletal muscle myosin far more than it enhances the rate of 
dephosphorylation of smooth muscle myosin [2,3]. 
*Corresponding author. Fax: (44) (1382) 22-3778. 
**These investigators have made equally important contributions to 
this study. 
It has long been recognised that the subunits which target 
PPl to the glycogen particles of striated muscle (GM) and liver 
(GL) must be distinct proteins. G, is a 124-125 kDa protein 
[4,5] which targets PPl to the membranes of the sarcoplasmic 
reticulum (SR) as well as to glycogen [6]. The glycogen-binding 
and PPl-binding sites are located in the amino-terminal third 
of GM [7], while the membrane association domain appears to 
comprise a sequence of 32 consecutive hydrophobic residues 
located near the C-terminus [4]. Phosphorylation of human G, 
at Ser-46 by an insulin-stimulated protein kinase(s) enhances 
the rate at which PPl dephosphorylates (activates) glycogen 
synthase and dephosphorylates (inactivates) phosphorylase ki- 
nase, and is thought to contribute to the stimulation of glyco- 
gen synthesis and inhibition of glycogenolysis by insulin [S]. In 
contrast, the phosphorylation of human G, at Ser-65 by cyclic 
AMP-dependent protein kinase (PKA), which occurs in re- 
sponse to adrenalin, triggers the dissociation of PPl from G,. 
As a result PPl is released from glycogen particles or SR mem- 
branes, impairing its ability to dephosphorylate glycogen-asso- 
ciated (glycogen synthase, glycogen phosphorylase [9-l 11) or 
SR-associated [6] substrates. This represents one of the mecha- 
nisms by which adrenalin inhibits glycogen synthesis and stim- 
ulates glycogenolysis in striated muscle [12]. 
In contrast to GM, the G, subunit suppresses the rate at 
which PPl dephosphorylates (inactivates) glycogen phosphory- 
lase and enhances the rate at which it activates glycogen syn- 
thase. As a consequence, the glycogen synthase phosphat- 
ase : phosphorylase phosphatase activity ratio of hepatic 
PPlG is far higher than that of muscle PPlG under the 
standard assay conditions [13-l 51. Moreover, incubation of 
hepatic glycogen particles with PKA and Mg-ATP is reported 
not to dissociate PPl from G, [16]. Instead, G, confers upon 
PPl a remarkable property, namely inhibition of the 
dephosphorylation of glycogen synthase by phosphorylase a 
(the active, phosphorylated form of glycogen phosphorylase). 
In the presence of glycogen, this inhibition occurs at nM con- 
centrations, about lOOO-fold lower than the K,,, for phosphory- 
lase a as a substrate, indicating that it is an allosteric effect 
[15,17]. Inhibition of the dephosphorylation (activation) of gly- 
cogen synthase by phosphorylase a provides an alternative 
mechanism for inhibiting glycogen synthesis when glycogenoly- 
sis is activated which, in striated muscle, is achieved by the 
PKA-catalysed phosphorylation of G,. In the liver, the level 
of phosphorylase a is elevated by hormones that increase the 
intracellular concentration of cyclic AMP (i.e. glucagon or 
adrenalin acting via /?-receptors) or calcium ions (vasopressin, 
angiotensin II or adrenalin acting via a-receptors) [l&19] and 
decreased by insulin (which reduces the level of cyclic AMP) 
or by glucose. When the circulating level of glucose rises, this 
sugar binds to hepatic phosphorylase a inducing a conforma- 
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klycogen-binding G, subunit of rat liver PPlG. The sequences of pep- 
I des isolated from the purified protein by digestion with either trypsin 
1 r Lys-C endoproteinase are underlined, and the broken lines show the 
I NO peptide sequences used to construct oligonucleotides for PCR. 
lional change that allows it to be dephosphorylated (inac- 
t ivated) more rapidly [20,21]. Moreover, the sensitivity of he- 
ilatic PPlG to phosphorylase a is itself highly regulated. It is 
j :reatly potentiated by glycogen [ 14,221, and may therefore only 
lperate in the fed state. 
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We recently purified hepatic PPlG to apparent homogeneity 
[23] by microcystin-Sepharose affinity chromatography [24]. 
The isolated enzyme retained the characteristic properties of 
hepatic PPlG and was composed of the PPl catalytic subunit 
complexed to a 33-kDa protein. The latter appeared to be G,, 
because it bound to glycogen and to phosphorylase a, while two 
tryptic peptides derived from it were similar to sequences found 
in the N-terminal domain of GM [23]. The small size of GL was 
surprising, since G, has a molecular mass of 124 kDa [4] and 
the presumed G-subunit homologue in S. cerevisae (GACl) is 
an 88 kDa protein [25]. However, the 33 kDa protein did not 
appear to be a proteolytic fragment of a larger precursor, be- 
cause it retained all the known properties of G, and no other 
PPl binding protein was detectable in rat or rabbit hepatic 
glycogen particles which had been isolated rapidly at @4”C in 
the presence of a proteinase inhibitor ‘cocktail’ [23]. Here we 
have determined the amino acid sequence of the 33-kDa protein 
from cloned cDNA and established by reconstitution with PPl 
that it is G,. 
2. Materials and methods 
2.1. Materials 
PPlG was purified from rabbit skeletal muscle [26] and the PPl 
catalytic subunit dissociated from GM by incubation for 2 h in 2 M LiBr 
and purified by gel filtration on Superose 12 in the presence of 0.5 M 
LiBr [2]. Sources of other Materials are given in [23]. 
2.2. Production of anti-(i, antibodies 
The peptides EAGRMVAPTVQEK and TQGMTEPYNGPDF cor- 
responding to residues 4456 and 239-251 of GL were conjugated to 
bovine serum albumin, and injected into a sheep at the Scottish Anti- 
body Production Unit (Carluke, Ayrshire, UK). The antibodies were 
affinity purified by chromatography of the antiserum on peptide-CH- 
Sepharose columns. 
2.3. Cloning of the rat liver glycogen-binding subunit of PPI 
Polymerase chain reactions were performed in 100 ~1 reactions using 
rat GL MAVDIIYSYS SYAPSLRRLP F ----TIXIS PXLUKPLRPC IQLOSXDlAQ 46 
I I I I 
YBPS 6VPQQlUSKDN FLIVPWLSDS LCEDIXVKAI FXPQFSPQPS 44 
YEPS KVPSQISKDM FLXVPWLSDS LCXDEXV--T PQPtW!PQPf 42 
rat GL RMVAPTVQEX KVX------ X XVSFADNQQL ALTUVXVPSX FDDPLDIPPN 90 
IIIIIII I I III I 
RRQSESSXW YVHTASSQQR RVSPADBPQF ALVSVXEPDT WXLP---SVS 91 
RRQ~DSSXDI YLDTPSSOOT RV~?ADS~O~ ILVSVXKrDC WELP---SAS 69 
rat GL ITILLDUIVS LTTAISESIV LDPPQPSADY LDFRWRLQTN HVCLK--NCV 138 
I I I II I II II 
TTrPLOXDAI QTELYVLSPL PDLPASXEDL MQ ---QLPVQ XAYLESTEYV 138 
TTTDLQTDAC WTIIYVLAPL IDLPSSXEDL MQ--- GQIQ XAILSETBSL 136 
rat G, LXXXAIAQTV XVQULATEXVVKIRYTFDTW XSrTDFPCQYVXDTYAQSDR 188 
IlllllIIII I II I 
PQSTSWXQII RVLMISYXXL VYVRWSLDDW QTHYDILAEY VPWSCDQ-ET 181 
LQSTSIWII R~LEVS~ VYVRYSLDPW_ QTHYDILAEY VPQSCDQ-ET 185 
rat GL DTFSTDISLP XXIQSYX-RN PTAVCYBCUQ QSYWDSWXQX BYRITRAKLR 237 
I II II 
CTIWSUKKQT UYTLVCQXXE 137 
QTFWSarplplQT =rICQXXE 135 
rat 6 STQQYTEPYU -QPDFOI--8 BDQPQSPRCS FOLPPIWPSY LQYXXLQPYY 284 
I I 
rabbit 
I I I I I 
PEPBPQXPLK EAPSKQKKQC LXVKSSKLES SETSEE--UU FSMSXIADTY 285--1109 
human QEPBPVlrEnX BVP_E?RQIXOC LXVXSSXEES SVTSLS--NH PXWPXWTDTY 183--1112 
Fig. 2. Comparison of the amino acid sequence of rat liver G,_ with the N-terminal regions of G, from rabbit and human skeletal muscle. Identities 
xe shown by vertical lines. The serine residues in G, that are phosphorylated by PKA (serines 46 and 65 in human G,) and by glycogen synthase 
kinase 3 (serines 38 and 42 in human GH) are marked by asterisks. Residues that are identical in GACl, GM and G, are underlined. 
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oligonucleotide-l (S-GTITCITT(T/C)GCIGA(T/C)AA(T/C)CA(A/ 
G)GG-3’) and oligonucleotide-2 (S-TTCCAIGT(A/G)TC(A/ 
G)AAIGTCATICT(A/G/T)AT-3’) (0.5 PM each primer), I x 10’ 
bacteriophage (1 PI), 1.5 mM MgCI, and Taq DNA polymerase Perkin- 
Elmer Cetus (Bucks, UK) as described by the suppliers. The major PCR 
product was purified by excision and electroelution from a 1% agarose 
gel and sequenced directly using oligonucleotides 1 and 2 as primers. 
The lZAP II rat liver cDNA library was hybridised at 55°C with the 
[a-“P]dATP labelled [27] PCR product, followed by washing in 1 x SSC 
(I 5 mM Na-citrate, 150 mM NaCl, pH 7.0) 0.1% SDS at 65°C. Two 
positively hybridising clones were purified and plasmids containing the 
cDNA inserts (both 2.3 kb) were excised according to the manufac- 
turer’s protocol (Stratagene, La Jolla, CA). DNA sequencing was per- 
formed in both directions on double-stranded plasmid DNA using an 
Applied Biosystems 373A automated DNA sequencer and Taq dye 
terminators. 
2.4. Expression of a glutathione-S-transferase-G, fusion protein in 
E. coli 
The open reading frame of G, was amplified by PCR using oligonu- 
cleotide 5’-CGCCCATATGGCCGTGGACATAGAATAC-3’, which 
creates an NdeI site(underlined) at the initiating methionine codon and 
oligonucleotide 5’-GCGCCTCGAGCACTAGTAATAGGGCCC- 
CAG-3’ which creates a XhoI site (underlined) just 3’ of the termination 
codon. Digestion of the PCR product with NdeI and XhoI allowed the 
complete coding region of G, to be cloned into NdeI-XhoI sites of the 
prokaryotic gene fusion expression vector pGEX-KG [28] which had 
modified to include a NdeI site in the linker region (C.G. Armstrong 
and P.T.W. Cohen, unpublished data). The final construct termed 
pGEX-GL, encoded glutathione S-transferase, followed by a thrombin 
cleavage sequence and the complete open reading frame of G,. After 
verifying that the sequence of the pGEX-G,_ construct was correct, the 
plasmid was transformed into the E. coli strain BL-21(DE3)pLysS and 
transformants selected on LB plates containing ampicillin (50 &ml) 
and chloramphenicol(25 @ml). Single colonies were grown to an A,“” 
of 0.4 at 37°C and expression of the fusion protein was induced at 28°C 
by addition of IPTG to a final concentration of 200 PM for 16-20 h. 
The bacteria were harvested by centrifugation, lysed by sonication in 
50 mM Tris-HCl, pH 7.5,200 mM NaCI, 2 mM EDTA, 2 mM EGTA, 
0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine, 0.2 mM phen- 
ylmethylsulphonyl fluoride, 0.02% (v/v) Brij-35. Insoluble protein was 
removed by centrifugation for 30 min at 40,000 x g and the fusion 
protein purified on glutathione-Agarose as in [29]. Only 75-150 pg of 
soluble G, protein was isolated from each litre ofbacterial culture, most 
of the expressed protein being insoluble and present in inclusion bodies. 
2.5. Preparation of phosphorylated proteins and phosphatase assays 
“P-Labelled rabbit skeletal muscle phosphorylase a (containing 1.0 
mol phosphate per mol subunit) was prepared by phosphorylation with 
phosphorylase kinase [30], and thiophosphorylase a was obtained in 
an identical manner except that unlabelled adenosine 5’-[y- 
thioltriphosphate replaced [y-“P]ATP. “P-Labeled rabbit skeletal mus- 
cle glycogen synthase was phosphorylated in the site-3 region to 1.5 
mollmol subunit with glycogen synthase kinase-3 [31]. The 
dephosphorylation of phosphorylase a (10 PM) and glycogen synthase 
(1 PM) were carried out using standard procedures [30]. One unit of PPl 
activity (U) was that amount which catalysed the release of 1 prnol of 
phosphate from phosphorylase a in 1 min. 
-54kb 
Fig. 3. Tissue distribution of the G, mRNA. A blot (Clonetech) of 
poly(A)’ RNA from different rat tissues was hybridised with a G, 
cDNA probe at 42°C according to the supplier’s protocol. The figure 
shows an autoradiograph of the blot developed after 24 h. Each lane 
contained approximately 2 pg of poly(A)+ RNA. 
-97 
-66 
-43 
-29 
Fig. 4. The GST-G, fusion protein binds to phosphorylase c1 specifi- 
cally. The GST-Gr fusion protein was electrophoresed on a 10% SDS/ 
polyacrylamide gel and either stained with Coomassie blue (lane 1) or 
transferred to nitrocellulose membranes and probed with 100 nM “P- 
labelled phosphorylase (I (lane 2) as described in [23]. In lane 3, the 
nitrocellulose membrane was probed with phosphorylase a containing 
5 mM magnesium acetate and 3 mM 5’-AMP..The arrows show the 
positions of the GST-G, fusion protein, GST and the molecular mass 
markers phosphorylase b (97 kDa), bovine serum albumin (66 kDa), 
ovalbumin (43 kDa) and carbonic anhydrase (29 kDa). 
3. Results 
3.1. Cloning of cDNA encoding the 33-kDu subunit of heputic 
PPIG fiotn a rat liver library 
The purified 33-kDa subunit was digested with either Lys-C 
endoproteinase or trypsin and a number of peptides were puri- 
fied and sequenced. Two peptides, RVSFADNQGLALTMVK 
and IRMTFDTWK, showed significant sequence similarities 
to residues 65-80 and 161-169 of G,, respectively, and were 
used to design suitable degenerate oligonucleotides for PCR 
(section 2.3). PCR using a rat liver cDNA library and these two 
oligonucleotides gave a 309 base pair fragment. The internal 
sequence of this fragment encoded amino acid sequences iden- 
tical to two other peptides isolated from the 33 kDa subunit, 
indicating that the PCR product did indeed encode a fragment 
of this protein. The PCR product was therefore used as a probe 
to screen the library, and 2 of the 18 positive clones identified 
(out of 500,000 phage screened) were purified and found to 
contain an identical open reading frame of 852 nucleotides 
encoding a 284 amino acid protein (Fig. 1). The molecular mass 
of this protein (32.56 kDa) is identical to the apparent molecu- 
lar mass of the purified protein estimated by SDS/poly- 
acrylamide gel electrophoresis [23]. Every peptide isolated (a 
total of 133 residues) was found in the deduced 284 amino acid 
sequence (Fig. l), including the C-terminal peptide LGPYY. A 
stop codon precedes the initiating ATG and the termination 
codon is followed almost immediately by two in-frame stop 
codons. 
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f g. 5. The GST-G, fusion protein transforms the catalytic subunit of PPI to a species with properties resembling those of hepatic PPlG. (A) The 
c ltalytic subunit of PPl was diluted in assay buffer to 1.5 U/ml (1.4 nM), and a 0.01 ml aliquot was incubated for 15 min at 30°C with 0.01 ml of 
t!,e indicated concentrations of purified bacterially expressed GST-G, fusion protein diluted in the same buffer. Phosphorylase phosphatase (PhP; 
closed circles) or glycogen synthase phosphatase (GSP; open circles) assays were then initiated with 0.01 ml of substrate. (B) The catalytic subunit 
o,‘PPl was incubated in the absence (closed circles) or presence (open circles) of GST-G, for 10 min at 30°C and then for 5 min with thiophosphorylase 
u before initiating the asssays with i2P-labelled glycogen synthase. The final concentrations in the assay were: PPl (0.5 nM), GST-G, (IO nM), glycogen 
s’,nthase (1 PM), thiophosphorylase a (as indicated). Activities are presented as a percentage of those measured in the absence of thiophos- 
p !norylase a. 
The amino acid sequence of the 33-kDa protein showed 23% 
Lientity to residues l--284 of the G, subunit from human skel- 
e.al muscle (Fig. 2), and 39% similarity if the most conservative 
s lbstitutions are included. The most striking regions of similar- 
i* y were those corresponding to residues 63-86, 144-166 and 
136-227 of human G, (-40% identity). 
Northern blotting demonstrated that the 5.4 kb RNA encod- 
i:lg the 33-kDa protein was specific to liver, being undetectable 
iqt brain, heart, kidney. lung, skeletal muscle, spleen and testis 
( ?g. 3). 
2 2. Expression of the 33-kDa protein in E. coli and 
reconstitution with PPI 
The 33-kDa protein was expressed in E. coli as a GST fusion 
r rotein, and after affinity chromatography on glutathione- 
f’,garose, the preparations showed two protein-staining bands 
with apparent molecular masses of 57 kDa and 24 kDa (Fig. 
d). The 57-kDa protein was recognised by an anti-GST anti- 
l- ody as well as by antibodies raised against two peptides from 
t le 33 kDa protein (section 2.2), while the 24-kDa species 
( which comigrated with GST) was only recognised by the anti- 
( iST antibody (data not shown). 
The 57-kDa fusion protein transformed the properties of the 
l’P1 catalytic subunit to those resembling hepatic PPlG. The 
: 7-kDa protein suppressed the phosphorylase phosphatase ac- 
I vity of PPl by 50% and enhanced its glycogen synthase phos- 
r hatase activity by 40% with maximal effects at 10 nM (Fig. 
5 A). Moreover, only after addition of the 57-kDa protein, did 
t le dephosphorylation of glycogen synthase become sensitive 
I I inhibition by phosphorylase a (Fig. 5B). The 57-kDa protein 
Literacted with ‘2P-labelled phosphorylase a (Fig. 4), and the 
Llteraction was specific because neither the 24-kDa protein nor 
any of the molecular mass standards (one of which is phor- 
phorylase b) were recognised by the phosphorylase a probe 
(Fig. 4). Moreover, the interaction of phosphorylase a with the 
57 kDa species was prevented by 5’-AMP (Fig. 4), which binds 
to phosphorylase a and is known to cancel the allosteric inhibi- 
tion of hepatic PPIG by phosphorylase a [20,21]. 
4. Discussion 
We have previously isolated PPlG from the glycogen-protein 
particles of rat liver and shown that the final preparation con- 
sists of the catalytic subunit of PPI complexed to a 33 kDa 
glycogen-binding protein [23]. Here we have cloned the cDNA 
encoding the 33 kDa protein, deduced its amino acid sequence, 
and provided definitive evidence that this protein is indeed G,. 
When expressed in E. coli, GST-G, bound to phosphorylase a 
specifically (Fig. 4) and transformed the properties of PPI to 
those characteristic of hepatic PPlG (Fig. 5). The 
dephosphorylation of phosphorylase a was suppressed, the 
dephosphorylation of glycogen synthase enhanced and the gly- 
cogen synthase phosphatase activity became sensitive to inhibi- 
tion by phosphorylase a. However, the dephosphorylation of 
phosphorylase a is only suppressed by 50% compared to 80% 
in native hepatic PPIG, and the concentration of phosphory- 
lase a which inhibited the dephosphorylation of glycogen syn- 
thase by 50% (about 1 PM in the absence of glycogen - Fig. 5) 
was 5-fold higher than for native hepatic PPIG [14]. These 
differences were not explained by the presence of GST at the 
N-terminus of the expressed protein, because removal of the 
GST-tag by cleavage with thrombin, did not enhance the ability 
of G, to modify the properties of PPl (data not shown). It is 
more likely that these differences are related to the highly aggre- 
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sated state of expressed GL, which could be pelleted by centrif- 
ugation for 30 min at 200,000 x g (data not shown). We have 
noticed that rat hepatic PPlG also has a strong tendency to 
aggregate in the absence of glycogen, and this property may 
explain, at least in part, the progressive loss of its distinctive 
properties during purification by conventional procedures, a 
problem which prevented its isolation for many years. 
G, and G, are structurally related, but the overall sequence 
similarity (23% identity, 39% similarity over the first 284 resi- 
dues of human G,) is surprisingly low (Fig. 2). GL lacks Ser-46 
of human GM whose phosphorylation activates muscle PPlG 
(see section I), as well as Ser-38 and Ser-42 of human G, which 
are phosphorylated by glycogen synthase kinase-3 in vitro (the 
functional significance of these phosphorylations is unclear) 
[7,32,33]. GL does retain a residue equivalent to Ser-65 of 
human G, whose phosphorylation by PKA triggers the disso- 
ciation of PPl from G, [9-l l] (Fig. 2). However, G, is poorly 
phosphorylated by PKA in vitro (G.M., unpublished experi- 
ments), perhaps because the sequence surrounding this residue 
is KRVSF and not RRVSF, and incubation with PKA under 
phosphorylating conditions is reported not to release PPl from 
hepatic glycogen particles [16]. Further work is needed to find 
out whether this serine residue in GL is phosphorylated by 
another protein kinase in vivo. G, lacks the membrane-associ- 
ation domain found near the C-terminus of GM [4]. This is 
consistent with an earlier finding that the form(s) of PPl asso- 
ciated with hepatic microsomes is distinct from hepatic PPlG 
1141. 
The regions showing most conservation between GL and GM 
(-40% identity) correspond to residues 63-86, 144-166 and 186 
227 of human G, (Fig. 2) suggesting that they may represent 
part of the PPl and/or glycogen-binding domains of these pro- 
teins. GACl, which may be the homologue of G,/G, in S- 
cerevisiue [26,34], shows weak homology to G,/GL. Nearly all 
the identities between GACl and GM/G, occur between resi- 
dues 144-166 and 186227 of human GM with no similarity to 
residues 63-86 of G,/G, (Fig. 2) [5,25]. Work is in progress to 
identify the PPl and glycogen binding domains on GM/G,, the 
high affinity binding site for phosphorylase a, and the region(s) 
responsible for modulating the substrate specificity of PPl. 
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